Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05426525 · ClinicalTrials.gov registry record · Phase 4
Use of Empagliflozin to Treat Prediabetes
A Phase 4 study of Overweight and Obesity and PreDiabetes, sponsored by Oregon State University.
- Active
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05426525 is a Phase 4 study of Overweight and Obesity and PreDiabetes that is active but no longer recruiting, run by Oregon State University. The registered enrollment target is 60 participants, below the 228-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05426525, a Phase 4 study of Overweight and Obesity and PreDiabetes, is active but no longer recruiting, sponsored by Oregon State University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this study is to identify how empagliflozin (a drug commonly used to treat type 2 diabetes) impacts skeletal muscle metabolic health among adults with prediabetes. Our aims are to: 1) Test the ability of empagliflozin to improve regulation of glucose metabolism (i.e., blood sugar) among overweight and obese individuals at risk for diabetes, and 2) Identify mechanisms to explain how empagliflozin may improve skeletal muscle glucose metabolism. We hypothesize empagliflozin will improve regulation of glucose metabolism due to changes in whole-body and skeletal muscle metabolism (e.g., increased rates of whole-body fat oxidation, evidence of impaired skeletal muscle mitochondrial respiratory function and increased energetic stress, lower accumulation of skeletal muscle lipids and improved skeletal muscle insulin signaling compared with placebo treatment).
Conditions Studied
Interventions
- DRUG Empagliflozin
- DRUG Multivitamin-Placebo
Study Locations (1)
Oregon
- Oregon State University - Corvallis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-10-13 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05426525
The ClinicalTrials.gov registry entry for NCT05426525 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 115 other Overweight and Obesity trials with a reported enrollment target (74% lower). The listed sponsor is Oregon State University, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Overweight and Obesity appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin is the first listed.
NCT05426525 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT05426525 about?
NCT05426525 is a clinical study titled "Use of Empagliflozin to Treat Prediabetes". The overall purpose of this study is to identify how empagliflozin (a drug commonly used to treat type 2 diabetes) impacts skeletal muscle metabolic health among adults with prediabetes. Our aims are to: 1) Test the ability of empagliflozin to improve regulation of glucose metabolism (i.e., blood su...
What is the current status of trial NCT05426525?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2022-10-13. Estimated completion is 2026-12.
What conditions does trial NCT05426525 study?
This clinical trial studies the following conditions: Overweight and Obesity, PreDiabetes, Prediabetic State.
What interventions are being tested in trial NCT05426525?
The interventions under investigation include: Empagliflozin (DRUG), Multivitamin-Placebo (DRUG).
Who is sponsoring clinical trial NCT05426525?
This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05426525 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overweight and Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Breathing & Blood Pressure
RECRUITING
-
A Pilot Factorial Trial of an Integrated Lifestyle Intervention
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
-
Cooking Skills to Improve Long-Term Weight Loss in Young Adults With Intellectual Disabilities
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.